High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir.
Dr Kris Kowdley and colleagues examined 8 weeks of treatment with this regimen.
In this phase 3, open-label study, the team randomly assigned 647 previously untreated patients with HCV genotype 1 infection without cirrhosis to receive ledipasvir and sofosbuvir (ledipasvir–sofosbuvir) for 8 weeks, ledipasvir–sofosbuvir plus ribavirin for 8 weeks, or ledipasvir–sofosbuvir for 12 weeks.
The team's primary end point was sustained virologic response at 12 weeks after the end of therapy.
|The rate of sustained virologic response was 94% with 8 weeks of ledipasvir–sofosbuvir|
|New England Journal of Medicine|
The rate of sustained virologic response was 94% with 8 weeks of ledipasvir–sofosbuvir, 93% with 8 weeks of ledipasvir–sofosbuvir plus ribavirin, and 95% with 12 weeks of ledipasvir–sofosbuvir.
As compared with the rate of sustained virologic response in the group that received 8 weeks of ledipasvir–sofosbuvir, the rate in the 12-week group was 1 percentage point higher, and the rate in the group that received 8 weeks of ledipasvir–sofosbuvir with ribavirin was 1 percentage point lower.
The team report that these results indicated noninferiority of the 8-week ledipasvir–sofosbuvir regimen, on the basis of a noninferiority margin of 12 percentage points.
The researchers observed that adverse events were more common in the group that received ribavirin than in the other 2 groups.
The team noted that no patient who received 8 weeks of only ledipasvir–sofosbuvir discontinued treatment owing to adverse events.
Dr Kowdley's team concludes, "Ledipasvir–sofosbuvir for 8 weeks was associated with a high rate of sustained virologic response among previously untreated patients with HCV genotype 1 infection without cirrhosis."
"No additional benefit was associated with the inclusion of ribavirin in the regimen or with extension of the duration of treatment to 12 weeks."